iNtRON Biotechnology Full Year 2024 Earnings: ₩79.00 loss per share (vs ₩292 loss in FY 2023)

Simply Wall St

March 13, 2025

iNtRON Biotechnology (KOSDAQ:048530) Full Year 2024 Results

Key Financial Results

Net loss: ₩2.59b (loss narrowed by 73% from FY 2023).
₩79.00 loss per share (improved from ₩292 loss in FY 2023).

earnings-and-revenue-history — KOSDAQ:A048530 Earnings and Revenue History March 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

iNtRON Biotechnology's share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for iNtRON Biotechnology (2 are a bit unpleasant!) that you need to take into consideration.

If you're looking to trade iNtRON Biotechnology, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if iNtRON Biotechnology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.